Figure 1.
Socio-demographic and medical characteristic bases (n = 33)_
| Variables | Intervention (n = 17) | Control (n = 16) | P-value | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age in years (mean, SD) | 47.06 | 8.45 | 45.31 | 9.81 | 0.587 |
| Educational level | 1.000 | ||||
| High | 10 | 30.30 | 10 | 30.30 | |
| Low | 7 | 21.20 | 6 | 18.20 | |
| Cancer type | 0.656 | ||||
| Ovarian | 4 | 12.10 | 2 | 6.10 | |
| Cervical | 13 | 39.40 | 14 | 42.40 | |
| Cancer stage | 0.296 | ||||
| Early | 8 | 24.20 | 11 | 33.30 | |
| Advanced | 9 | 27.30 | 5 | 15.20 | |
| Chemo cycle | 1.000 | ||||
| ≤3 | 12 | 36.40 | 12 | 36.40 | |
| >3 | 5 | 15.10 | 4 | 12.10 | |
| Regimen | 1.000 | ||||
| Platinum | 15 | 45.50 | 15 | 45.50 | |
| Non-platinum | 2 | 6.00 | 1 | 3.00 | |
| PFS Score day 1 (mean, SD) | 4.29 | 1.75 | 3.54 | 1.68 | 0.220 |
| HADS day 1 (mean, SD) | 1.37 | 0.29 | 1.42 | 0.38 | 0.622 |
Difference in PFS and HADS mean scores within the 2 groups (n = 33)_
| Variables/groups | Time | P-value | Effect size (ES) | ||
|---|---|---|---|---|---|
| Day 1 (pretest) | Day 4 | Day 8 (posttest) | |||
| PFS Score (mean, SD) | |||||
| Intervention (n = 17) | 4.29 ± 1.75 | 5.03 ± 1.99 | 3.52 ± 1.52 | 0.012* | 0.443 |
| Control (n = 16) | 3.54 ± 1.68 | 4.65 ± 2.01 | 3.57 ± 1.90 | 0.152 | - |
| HADS Score (mean, SD) | |||||
| Intervention (n = 17) | 1.37 ± 0.29 | 1.34 ± 0.25 | 1.28 ± 0.36 | 0.767 | - |
| Control (n = 16) | 1.42 ± 0.38 | 1.42 ± 0.35 | 1.46 ± 0.35 | 0.793 | - |
Comparison of median cortisol level within and between the 2 groups (n = 33)_
| Variable | Intervention (n = 17) | Control (n = 16) | P-valuea | ||
|---|---|---|---|---|---|
| Median (IQR1-IQR3) | Min–Max | Median (IQR1-IQR3) | Min–Max | ||
| Cortisol level | |||||
| Day 1 | 0.38 (0.31–0.64) | 0.25–0.88 | 0.51 (0.38–0.70) | 0.20–2.35 | 0.15 |
| Day 8 | 2.97 (1.26–5.18) | 0.39–6.91 | 2.30 (0.99–9.09) | 0.43–23.38 | 0.83 |
| P-valueb | 0.0003* | 0.001* | |||